Location History:
- Duncanville, TX (US) (1998 - 2006)
- San Diego, CA (US) (1996 - 2009)
- Dallas, TX (US) (1999 - 2022)
Company Filing History:
12 out of 576 
7 out of 5,470 
4 out of 601 
Years Active: 1996-2024
Title: Innovator David John Mangelsdorf: Pioneering Treatments for Exocrine Pancreatic Insufficiency
Introduction
David John Mangelsdorf is an esteemed inventor based in Dallas, Texas, who has made remarkable contributions to the field of medical therapy. With a portfolio of 21 patents, his work primarily focuses on innovative methods for treating secretory disorders, particularly exocrine pancreatic insufficiency.
Latest Patents
Among his latest patents, one notable invention is titled "Methods and Compositions for the Treatment of Exocrine Pancreatic Insufficiency." This invention provides novel treatment approaches by administering fibroblast growth factor 21 (FGF21) or its derivatives. These methods are applicable for conditions such as exocrine pancreatic insufficiency resulting from various causes, including cystic fibrosis, alcoholism, and pancreatitis. Furthermore, the invention addresses salivary flow disorders like Sjögren's syndrome.
Another significant patent is "Use of FGF21 in Methods of Increasing Exocrine Pancreatic Secretion." This innovation expands on his previous work by offering treatments that enhance pancreatic secretions, which can be beneficial for patients undergoing related surgical procedures and for those suffering from chronic disorders.
Career Highlights
David John Mangelsdorf has an impressive career marked by his association with prominent research institutions. He has worked at the Salk Institute for Biological Studies and the University of Texas System, where his research has led to groundbreaking advancements in understanding and treating pancreatic disorders.
Collaborations
Throughout his career, Mangelsdorf has collaborated with notable scientists, including Ronald Mark Evans and Richard Alan Heyman. These collaborations have enriched his work and furthered the development of innovative therapies in the field.
Conclusion
David John Mangelsdorf stands out as a significant inventor in the medical field, particularly regarding the treatment of exocrine pancreatic insufficiency. His innovative methods and compositions continue to provide hope for patients suffering from secretory disorders, marking him as a notable figure in modern medical inventions. With a remarkable track record of patents and collaborations, Mangelsdorf's contributions will undoubtedly influence future research and healthcare practices.